43575
Off
indegene ipo

Indegene IPO

  • Status: Closed
  • RHP:
  • ₹ 14,190 / 33 shares

    Minimum Investment

IPO Listing Details

  • Listing Date

    13 May 2024

  • Listing Price

    ₹659.70

  • Listing Change

    45.95%

  • Last Traded Price

    ₹658.50

IPO Details

  • Open Date

    06 May 2024

  • Close Date

    08 May 2024

  • IPO Price Range

    ₹ 430 to ₹ 452

  • IPO Size

    ₹ 1841.76 Cr

  • Listing Exchange

    BSE, NSE

  • Listing Date

    13 May 2024

With just a few clicks, Invest in IPOs!

+91

By proceeding, you agree to all T&C*

hero_form

Indegene IPO Subscription Status

Last Updated: 10 May 2024 11:42 AM by 5Paisa

Established in 1998, Indegene Limited digital-led commercialization services. The company offers these services to a wide range of industries including the life sciences industry, including biopharmaceutical, emerging biotech and medical devices. These help the clients in drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of products.

The company enjoys client relationships with all the 20 largest pharmaceutical companies globally in terms of revenue for FY 2023. It has four business verticals:

●    Enterprise Commercial Solutions
●    Omnichannel Activation  
●    Enterprise Medical Solutions 
●    Enterprise Clinical Solutions and consultancy services

Indegene had 65 active clients as of December 2023 and runs offices in India as well as North America, Europe and Asia.

Peer Comparison
No listed peers. 

For More Information:
Webstory on Indegene IPO

Profit and Loss

Balance Sheet

Particulars (in Rs. Crores) FY23 FY22 FY21
Revenue from operations 2306.13 1664.60 966.27
EBITDA 454.18 265.91 263.96
PAT 266.09 162.81 185.68
Particulars (in Rs. Crores) FY23 FY22 FY21
Total Assets 2203.86 1353.46 596.04
Share Capital 44.29 0.35 0.31
Total Borrowings 1140.14 589.56 262.95
Particulars (in Rs. Crores) FY23 FY22 FY21
Net cash generated from / (used in) operating activities 130.21 297.04 172.03
Net cash from / (used in) investing activities -893.34 -160.20 -24.24
Net cash flow from / (used in) financing activities 333.08 233.47 -131.50
Net increase (decrease) in cash and cash equivalents -430.04 370.31 16.27


Strengths

1.    The company has domain expertise in healthcare.
2.    It also has digital capabilities and an in-house developed technology portfolio.
3.    It has a track record of establishing long-standing client relationships.
4.    It has 17 offices located across North America, Europe and Asia.
5.    The company has experience in creating value through acquisitions.
6.    Experienced management team.

Risks

1.    A majority of our revenues are derived from our Subsidiaries.
2.    The life sciences operations industry is highly competitive
3.    The company derives a majority portion of its revenues from large clients located in North America and Europe.
4.    High working capital requirements. 
 

Will You Apply for Indegene IPO?

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

FAQs

Indegene IPO opens from 6th May to 8th May 2024.

The size of Indegene IPO is ₹1,841.76 cr. 

To apply for Indegene IPO, follow the steps given below:

●    Login to your 5paisa account and select the issue in the current IPO section    
●    Enter the number of lots and the price at which you wish to apply for the  Indegene IPO.    
●    Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.    

You will receive a mandate notification to block funds in your UPI app.
 

The price band of Indegene IPO is set at ₹430 to ₹452 per share.

The minimum lot size of Indegene IPO is 33 shares and the minimum investment required to apply for the IPO is ₹14,190.

The share allotment date of Indegene IPO is 9th May 2024.

The Indegene IPO will be listed on 13th May 2024.

Kotak Mahindra Capital Company Limited, Citigroup Global Markets India Private Limited, J.P. Morgan India Private Limited, and Nomura Financial Advisory and Securities (India) Private Limited are the book-running lead managers for Indegene IPO.

Indegene Limited will use the proceeds from the IPO for:

●    To repay or prepay debt obtained by ILSL Holdings, Inc. a Material Subsidiary.
●    To fund the working expenditure requirements of the company and its material subsidiary Indegene, Inc.
●    To fund inorganic growth.
●    General corporate purposes.